Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants with a novel competitive multiplex assay

Validation of a novel multiplex RBD-ACE2 inhibition assay to measure SARS-CoV-2 neutralizing antibodies in plasma to WT RBD and Spike (S1)

A subset of previously described (38) plasma samples collected from a cross-sectional cohort of Australian adults recovered from SARS-CoV-2 infection were chosen to firstly evaluate the performance of this assay with regard to its ability to quantitate ACE2 inhibitory antibodies from SARS-CoV-2 convalescent subjects. Subsequently, we then sought to determine whether NAbs in the SARS-CoV-2 positive plasma could inhibit ACE2 receptor binding in a similar manner as the virus microneutralization assay (39). In this assay, inhibition of the SARS-CoV-2 RBD-ACE2 interaction by antibodies in SARS-CoV-2 convalescent plasma was observed as dose-dependent decrease in fluorescent ACE2 measured as MFI (Median Fluorescence Intensity) bound to immobilised RBD, whereas the MFI of SARS-CoV-2 negative plasma remained high across the 8-point 2-fold serial dilution (Figure 1B), demonstrating that the specific inhibition of the SARS-CoV-2 RBD–ACE2 interaction by plasma from convalescent SARS-CoV-2 subjects occurs in a dose-dependent manner (Figure 1C). The capacity of antibodies in SARS-CoV-2 convalescent plasma to inhibit the interaction between ACE2 and RBD in this assay was detected in most subjects in this cohort (median, 40.5%; IQR, 32.9%–60.4%), with 31% subjects exhibiting more than 50% ACE2 inhibition activity Figure 1D. In comparison, just under a quarter (23%) of subjects exhibited more than 50% inhibition activity against S1 (median, 33.1%; IQR, 28.4%–48.3%) (Figure 1E), suggesting that the full S1 protein may provide additional stability to the ACE2-RBD interaction. A nominal cut-off of 20% was set based on a panel of SARS-CoV-2 negative subjects (Supplementary Figure 1A. To further validate this assay, each plasma sample’ s relative half-maximum inhibitory concentration (IC₅₀) titer to RBD (WT) and spike (S1) was determined from the 2-fold 8-point dilution. Relative IC₅₀values of the ACE2-RBD versus ACE2-S1 interaction by plasma NAbs strongly correlated (r=.94, p< 0.0001) Figure 1F, and calculated ACE2 % inhibition at a 1 in 100 dilution of plasma positively correlated with RBD IC₅₀, (r=.96, p< 0.0001) Figure 1G, suggesting that a 1 in 100 dilution of plasma would be closely representative of the relative IC₅₀.

In order to determine how well this assay could detect NAbs in comparison to a virus neutralization assay (39), relative IC₅₀ values to RBD and S1 were correlated to a microneutralization assay using SARS-CoV-2 infection of Vero cells. As shown in Figure 1H and Figure 1I, there was a strong correlation between the two assays for RBD-ACE2 inhibition (r = 0.8, p< 0.0001) and S1-ACE2 inhibition (r= 0.75, p< 0.0001). In addition, we examined the relationship between ACE2 inhibition and IgG RBD binding (Figure 1J), and found a moderate correlation between the two (r = 0.58, p=0.0002), which suggests that inhibition may also be mediated by other antibody isotypes such as IgA and IgM or to other key regions of the S1 protein, such as the N-terminal domain (NTD) (40). The multiplex assay was determined to be robust (r² = 0.9) Supplementary Figure 1B by comparing the repeatability of the % ACE2-RBD inhibition values obtained by the cohort of plasma samples when tested by two operators in two independent experiments on separate days, with the mean % ACE2-RBD inhibition once again demonstrated to correlate strongly to the microneutralization assay (Supplementary Figure 1C).

Considering mAbs are of increasing interest for therapy or prophylaxis of SARS-CoV-2, we evaluated the ability of this assay to specifically measure mAbs that neutralize the ACE2-RBD interaction. Here we tested two commercially available neutralizing antibodies (one human and one mouse), and two negative controls for RBD binding and ACE2 inhibition. The first negative control was an unrelated human mAb against influenza, and the second was CR3022, a neutralizing mAb which has been described to bind RBD at an epitope that does not overlap with the ACE2 binding site of SARS-CoV-2 and therefore is unable to block the ACE2-RBD interaction (41). As demonstrated in Figure 1K and 1L, both the human and mouse neutralizing mAbs demonstrated a very similar pattern of RBD binding and ACE2 inhibition. In contrast the absence of binding and inhibition of ACE2 by a non-specific influenza mAb confirmed the specificity of this assay. CR3022 binding to RBD coincided with the absence of ACE2 inhibition further validating the specific ability of this assay to evaluate neutralizing antibodies which specifically inhibit the RBD-ACE2 receptor interaction.

Validation of an RBD natural variant multiplex array

Upon validation of the multiplex RBD-ACE2 assay to WT RBD and S1, we sought to expand the assay multiplexing 23 RBD natural mutants selected from the GISAID RBD surveillance repository at the time (June 2020), as well as RBD variant S477N which emerged and rose to be the second most frequent variant in the following months. A total 25 variants including the WT were studied. Figure 2A illustrates the position of these variants on the RBD, and Figure 2B displays the more recent observed frequency of these variants according to the GISAID repository, with variant N501Y, currently the most frequent RBD variant worldwide (a key mutation present in the newly emergent B.1.1.7, B.1.351, B.1.1.70 and P.1 strains). The RBD variant array was set up by coupling each of these 25 variants to an individual “ bead region” corresponding to a unique spectral signature, with coupling efficiency across the RBD variant proteins onto the carboxylated magnetic microspheres verified with an anti-His Tag antibody (Supplementary Figure 2). This was determined by comparing the mean MFI of each of the coupled RBD proteins to the WT, with coupling across all the RBD variants determined to be comparable to the WT RBD. We also correlated the IgG binding (r² =0.97) and ACE2 inhibition (r² =0.99) of each of the variants on their own (single-plex) as well as when in combination with all other variants (multi-plexed) (Supplementary Figure 3A and 3B), which confirmed the absence of any undesirable effect or significant loss of signal as a result of multiplexing all RBD variant proteins simultaneously in a single well.

• Download figure
• Open in new tab

Figure 2. Characterization of RBD variants in the Multiplex array

A. Structure of novel coronavirus spike receptor-binding domain (RBD) complexed with its receptor ACE2 (PDB ID code 6LZG) highlighting the amino acid positions of 24 RBD natural variants selected from the GISAID repository in June 2020, with the subsequent inclusion of S477N and their proximity to the RBD-ACE2 interface. The structural illustration was generated using PyMol. Variants with a significantly higher affinity to ACE2 as determined in our multiplex assay are highlighted in blue. B. Cumulative Frequency of variants ranked from most frequently isolated to less frequent which are included in the multiplex array. Frequency of genomes is based on high quality 2019-nCov genome sequences reported by the GISAID database as of 9th^th March 2021. Variants with a significantly higher affinity to ACE2 as determined in our multiplex assay are highlighted in blue. C. Relative EC₅₀.values (μg/mL) obtained for each of the variants. Values are color-coded blue for EC₅₀ <10 μg/mL and red for EC₅₀.values >10 μg/mL. D. Mean fold difference for each RBD variant EC₅₀ value relative to WT RBD. Data is shown as the mean ± SEM of (n=4) independent experiments. Bars for variants with more than a 2-fold difference in affinity to the WT RBD are colored blue. Bars for variants with a slightly increased affinity (< 2-fold) are colored white. Variants with a weaker EC₅₀ value relative to WT are coloured red. E. Bio-layer interferometry sensograms of immobilized ACE2 with 2-fold 6-100 nM serial dilutions of SARS-CoV-2 RBD variants in solution. Binding curves representative of two independent experiments for each variant are plotted (solid-colored lines), globally fitted to a 1:1 binding model (black line).

• Download figure
• Open in new tab

Figure 3. Mapping mutations to the RBD that affect recognition by monoclonal antibodies

A. Relative EC₅₀. RBD binding of each mAb to each of the RBD variants B. Relative IC₅₀. RBD inhibition of each mAb to each of the RBD variants. C. RBD natural variant ACE2-RBD relative IC₅₀. inhibition relative to RBD WT. Blue -Stronger inhibition of RBD variants relative to WT (IC₅₀. < RBD WT) Orange-Weaker inhibition of RBD variants relative to WT (>1-6 fold RBD WT IC₅₀.). Red >6 fold weaker RBD WT IC₅₀.ie. very poor/absence of inhibition. D. Relative IC₅₀. RBD inhibition of each mAb to each of the RBD variants performed in a non-competitive format where mAbs were pre-incubated prior to addition of ACE2. E. Relative EC₅₀. Binding of mAbs to Alanine (or Serine if previously alanine) RBD mutants generated of selected RBD variants via multiplex array.

Affinity of RBD variants to ACE2

To evaluate how the array of RBD variants affected binding to ACE2 in our assay, a 2-fold 12-point serial dilution of ACE2 starting from a final concentration of 160µg/ml per well was performed, and a relative EC₅₀ for each of the variants was determined (Figure 2C). The calculated difference in the relative EC₅₀ of each variant was then compared to RBD WT (Figure 2D), with the majority of RBD variants exhibiting a similar or weaker relative EC₅₀ when compared to the WT RBD. A trend consistent with the observation that many missense mutations often negatively impact ACE2 binding (42). Nevertheless, we found some variants demonstrated significantly enhanced binding to ACE2 relative to WT SARS-CoV-2 RBD. These were N501Y, Q493L, S494P and S477N which demonstrated the lowest overall relative EC₅₀ values (0.2, 3.6, 6.3 and 8.3 µ g/ml respectively) as determined by our ACE2-RBD multiplex assay (Figure 2C).

Though it is now well known that N501Y, which is the shared mutation in the B.1.1.7, B.1.351, B.1.1.70 and P.1 lineages, is predicted to have a higher affinity for ACE2, (42), here we sought to characterize the binding kinetics of N501Y to WT RBD and other potential high affinity variants. Based on the relative EC₅₀. values observed in our multiplex assay, we selected these high affinity variants, and the emerging N439K variant present in currently circulating linage B.1.258, as well as E484K which is a mutation shared by B.1.351, B.1.525 and P lineages to be profiled and compared for their binding kinetics to ACE2 using Bio-layer interferometry (BLI). In addition, one variant that showed a reduced affinity for ACE2 (E484D), was also selected to be profiled for comparison.

BLI profiles of the RBD variants binding to ACE2 (Figure 2E) confirm that indeed variant N501Y demonstrates an enhanced affinity for the ACE2 receptor, with an almost a 5-fold increase in affinity (K_D 6.4nM vs 29.4nM), which is driven by a much slower off-rate of this variant (t½ 329.1 s (k_dis 0.00210 1/s) vs t½ 83.7 s (k_dis 0.00825 1/s)) compared to the WT. Variant S477N also demonstrated enhanced (K_D 10 nM) affinity for ACE2, although variant Q483L (K_D 21 nM) demonstrated a slower off-rate t½ 211.5 s vs t½ 160.6 s by comparison. N439K and S494P had weakly enhanced overall affinity for ACE2, K_D 25.2 nM and 26.1 nM, respectively, compared to the WT RBD (29.4nM). The enhanced affinity of N439K was the result of the almost 1.5 fold slower off-rate t½ 111.3 s (k_dis 0.00620 1/s) vs t½ 83.7 s (k_dis 0.00825 1/s) of the WT. Confirming multiplex ACE2 EC₅₀ assay observations, variants E484K and E484D demonstrated reduced affinity to ACE2 (K_D 37.2 nM, and K_D 110.8 nM respectively).

Mapping mutations to the SARS-CoV-2 RBD that affect recognition by monoclonal antibodies

We next sought to apply the multiplex assay to map potential escape mutations using a panel of six previously characterized mAbs. These were human mAbs COVA2-15 and COVA-18, (43), C002 and C135 (44), SAD-35 (Acro Biosystems) and mouse mAb MM43 (Sino Biologicals). First, we assessed binding of each mAb to the RBD variants by determining the relative EC₅₀ (Figure 3A), and second, we determined ACE2 inhibition of these mAbs to these variants by calculating the relative IC₅₀ (Figure 3B), from an 8-point 4-fold serial dilution of each mAb. Though all six mAbs bound (Figure 3A) and inhibited (Figure 3B) the SARS-CoV-2 RBD WT with relatively high affinity, they however differed in the extent to which they bound and inhibited each of the RBD variants. Variants with mutations at position 446 and 484 (with the exception of E484D) of the RBD prominently demonstrated antibody escape and consequently poor inhibition. COVA2-15 and C135 demonstrated escape to G446V, while COVA2-15 demonstrated a loss of binding and inhibition to S494P. mAb C002 demonstrated escape from variants E484A, E484K, E484Q and Q493L. Furthermore, N501Y demonstrated an overall reduction in its ability to be inhibited across all mAbs as demonstrated by significantly weaker relative IC₅₀ values, compared to the WT (Figure 3C), despite all mAbs having the capacity to bind RBD variant N501Y with relatively high affinity (Figure 3A).

We next generated a panel of 15 of the RBD variants where we mutated the amino acid variants to alanine, (or to serine if alanine was already present) (Figure 3E), in order to further confirm which amino acid positions are essential for mAb epitope binding. We found that for a subset of RBD variants, immune escape occurs due to a reduction or absence of mAb binding at key amino acids, such as position 446 and 490. In contrast, other positions, such 493, 494, and 501 were relatively unaffected by the alanine substitution, suggesting that alternative immune escape mechanisms beyond loss of mAb recognition may be involved, with the attenuation of the neutralizing response, and escape particularly by the N501Y mutation most likely a result of this variant’ s significantly enhanced affinity to ACE2.

The majority of current in vitro SARS-CoV-2 neutralization assays first allow antibodies to bind the RBD before subsequent incubation with the ACE2 receptor or ACE2 expressing cells. This approach has the potential to bias the assay to allow for maximal NAb neutralization, thus reducing the influence of RBD variant affinity to the ACE2 receptor. In light of this, we sought to evaluate how mAb pre-incubation followed by incubation with the ACE2 receptor compared to our original competitive format of the ACE2-RBD inhibition assay where all components are added simultaneously. Pre-incubation of mAbs in the absence of ACE2 was found to significantly overestimate the neutralizing capacity of the mAbs (Figure 3D), conferring the mAb a competitive advantage by allowing it to neutralize the RBD in the absence of competing ACE2. Although similarities in the overall trend of neutralization compared to the WT emerge (Supp Figure 4), the much lower relative IC₅₀ values obtained in comparison to the competitive assay performed in parallel (Figure 3D), appreciably reduces the resolution of the differences in the neutralizing response between variants, in particular to N501Y, to which all mAbs demonstrated an attenuated neutralizing response in the competitive assay (Figure 3B). This observation was however not as apparent in the non-competitive assay (Figure 3D).

• Download figure
• Open in new tab

Figure 4. Mapping mutations to the RBD that affect inhibition of ACE-RBD by polyclonal antibodies

A. Percentage ACE2-RBD inhibition of a panel of n=20 convalescent samples (1 in 100 plasma dilution), demonstrating inhibition of RBD WT-ACE2 binding, mapped to the array of RBD variants in the multiplex assay. B. Percentage ACE2 Inhibition ratio to the WT for each subject to each RBD variant. C. Percentage of subjects which were able to block (inhibition >20%) binding to each RBD variant in the array. Data represents the mean of replicates.

Mapping mutations to the SARS-CoV-2 RBD that affect recognition by convalescent human plasma antibodies

Having established the array of RBD natural variants and tested these with a panel of mAbs, we sought to evaluate recognition of the variants by polyclonal immune plasma from 20 individuals who had recovered from SARS-CoV-2 infection a mean of 36 days earlier (Table S1). These samples were collected early in the pandemic (March-April 2020) before the detection of the N501Y variant in Australia.

Plasma samples were tested at a single-point dilution of 1 in 100 across the array of natural RBD variants, based on the previously strong correlation of this dilution with relative IC₅₀ values (Figure 1G). As observed in Figure 4A, most subjects demonstrated a reduction in the inhibition of most RBD variants, with the neutralizing response to variant N501Y being the most significantly attenuated, with many subjects demonstrating a ratio of less than 0.5 to that observed with the WT (Figure 4B), equating to over a 2-fold decrease in % inhibition to variant N501Y compared to the WT. Similar to the findings observed with the panel of mAbs, many convalescent plasma samples were able to bind the N501Y mutant with similar affinity to WT (Supplementary Figure 5), however likely due to the enhanced affinity of N501Y to ACE2, polyclonal convalescent plasma demonstrated a reduced ability to inhibit the ACE2-RBD interaction (Figure 4A and 4B) to this variant. Figure 4C illustrates the % of subjects which had a neutralizing response (i.e. >20%) to each RBD variant, with the lowest proportion of responders observed to occur to high affinity variants N501Y (30%) and Q493L (35%). This was followed by N439K (60%), N477N (65%), and E484K (65%). These results suggest that despite having the capacity to inhibit WT RBD, many convalescent individuals may not generate antibodies with high enough affinity capable of competing with RBD variants with an enhanced affinity to ACE2.

Materials Availability

This study did not generate new unique reagents.

Data and code Availability

The raw datasets supporting the current study are available from the corresponding author on request.

Ethics statement

The study protocols were approved by the University of Melbourne Human Research Ethics Committee and all associated procedures were carried out in accordance with approved guidelines. All participants provided written informed consent in accordance with the Declaration of Helsinki.

Plasma

Patients who had recovered from COVID-19 and healthy controls were recruited through contacts with the investigators and were invited to provide a blood sample as previously described (38). For all participants, whole blood was collected with sodium heparin anticoagulant, and plasma was collected and stored at -80 °C until use.

Recombinant proteins

DNA encoding the truncated human ACE2 ectodomain (residues 19–613) with a C-terminal AVI-tag and 6xHis-tag was synthesised (IDT) and cloned into a pHLSec expression plasmid. Plasmid DNA was used for transient expression in Expi293F cells using Expifectamine 293 transfection kits (Thermofisher Scientific). Expression supernatant was harvested at day 6, and dialysed into 10mM Tris pH 8.0. ACE2 was subsequently purified using weak anion exchange (DEAE Sepharose, Cytiva), followed by size exclusion chromatography (Superdex 200, Cytiva). Protein was then biotinylated enzymatically using BirA enzyme and further purified using strong anion exchange (MonoQ, Cytiva).

Human IgG1 Anti-SARS-CoV-2 RBD Neutralizing Antibody, (#SAD-S35, Acro Biosystems) and mouse IgG2b SARS-CoV-2 RBD Neutralizing Antibody (#40592-MM43, Sino Biologicals) were used as positive controls. An in-house influenza mAb and human monoclonal CR3022 which binds RBD at an epitope that does not overlap with the ACE2 binding site of SARS-CoV-2 and therefore shows no competition with ACE2 (41), were used as negative controls. The heavy and light chain sequences of previously described monoclonal antibodies COVA2-15 and COVA-18 (43), and C002 and C135 (44) were synthesised and cloned into human IgG1 expression plasmids. These were expressed in Expi293 cells and purified using Protein A.

RBD natural variant multiplex array

For the natural variant array 24 SARS-CoV-2 RBD variants were selected from the GISAID RBD surveillance repository (June 2020) for inclusion in the array. The WHU1 wild type (WT) isolate (2), SARS-CoV-2 RBD sequence (GenBank: MN908947.3. (amino acids 319–541; RVQP…CVNF), with the signal peptide (amino acids 1–14; MFVF…VSSQ) and a hexahistidine tag cloned into pcDNA3.4 vectors by Genscript Corporation (Piscataway, NJ, USA) was used as the original WT sequence. SARS-CoV-2 Spike S1 (#40591-V08H, Sino Biologicals) recombinant protein was also included in the array. RBD variants were expressed in Expi293 HEK cells (ThermoFisher), maintained in suspension at 37 C and 8% CO₂. Cells were transfected at a density of 3 x 10⁶ with 1 µg of plasmid DNA for 1 mL of culture and ExpiFectamine™ 293 reagent diluted in Opti-Mem™ (ThermoFisher) following the manufacturer’ s protocol. 22 hours after transfection, ExpiFectamine™ 293 transfection Enhancer 1 and 2 (ThermoFisher) was added to transfected cells along with lupin peptone. Six days after transfection, the supernatant was collected by centrifugation, and 10 mM MgCl₂ was added to improve binding to the column and filtered through a 0.22 µm filter. RBD variants were purified by loading the supernatant onto a 1 mL Ni Excel column (GE Healthcare). Columns were equilibrated and washed using Dulbecco’ s phosphate buffered saline (DPBS). RBD variants were eluted using 300 mM imidazole, 100 mM NaCl DPBS buffer. A second purification step was performed by loading the eluate on a S75 increase 10/300 pg gel filtration column (GE Healthcare). Protein concentration was determined by absorbance measurement at 280 nm and purity was determined using SDS-PAGE.

Alanine mutants were generated by Genscript Corporation (Piscataway, NJ, USA). Where an alanine was naturally present, a serine substation was used instead. Recombinant proteins were expressed from HEK293 cells and subsequently purified using Ni-NTA columns. Protein concentration was determined by absorbance measurement at 280 nm and purity was determined using SDS-PAGE.

RBD variant multiplex bead cocktails were generated as previously described (57) Briefly, each respective RBD protein was coupled to a distinct magnetic carboxylated bead region (Bio Rad) using a two-step carbodiimide reaction at a ratio of 1 million beads to 5 µg of each RBD protein. RBD multiplex assays were conducted in black, clear bottom 384-well plates (Greiner Bio-One). 20µl of RBD natural variant cocktail (700 beads of each bead region per well) were added to 10 µl of mAbs at a starting final concentration of 80nM per well, prepared as 8-point 4-fold titrations in assay buffer (0.1% BSA/PBS). For the ACE2 inhibition assay 20µl of 25µg/ml of AviTagged Biotinylated ACE2 was subsequently added to all wells, whereas 20µl of assay buffer was added to RBD antibody binding assay wells, to bring the total final volume per well to 50µl. Each plate was incubated for 2 hours on a plate shaker at RT, before being washed twice in 0.05% PBS Tween 20. For the ACE2 inhibition assay, binding was detected with 40 µl of Streptavidin, R-Phycoerythrin Conjugate (SAPE) (#S866, Thermo Fisher) at 4µg/ml added for 1 hour, followed by the addition of 10 µl of 10 µg/ml of R-Phycoerythrin Biotin-XX Conjugate (#P811, Thermo Fisher), incubating for an additional hour. Relative RBD antibody binding was detected using anti-human IgG R-Phycoerythrin (PE) Conjugate (#9040-09, Southern Biotech) at 1.3µg/ml for 2 hours. For both assays’ plates were incubated on a plate shaker at RT before being washed three times. 60 µl of sheath buffer was added to each well, with plates left to shake for 10 minutes on a plate shaker prior to acquisition on a FlexMap3D(tm) (Luminex Corporation). The binding of ACE2 or IgG detected as phycoerythrin-labelled reporter is measured as MFI (Median Fluorescence Intensity). Coupling efficiency of the recombinant RBD was assessed as above using the anti-His Tag antibody (#A00174, GenScript), in place of the IgG detector conjugate.

The non-competitive ACE2 inhibition assay was performed as above with the exception that antibody was allowed to incubate first for 1 hour with the RBD variant bead cocktail, before addition of biotinylated ACE2 for a further hour.

Microneutralization test

The virus microneutralization test was performed as previously described (38, 39). Briefly SARS-CoV-2 isolate CoV/Australia/VIC01/2020 (58) was passaged in Vero cells, and samples were serially diluted before the addition of 100 TCID₅₀.of SARS-CoV-2 in MEM/0.5% BSA and incubation at room temperature for 1 h. Residual virus infectivity in the plasma/virus mixtures was assessed in quadruplicate wells of Vero cells incubated in serum-free media containing 1 μg ml^-1 of TPCK trypsin at 37 °C and 5% CO₂ viral cytopathic effect was read on day 5.

Biolayer Interferometry (BLI)

The affinity and kinetic constants of selected RBD variants to the ACE-2 receptor were measured by BLI performed on the Octet Red instrument (FortéBio). Assays were performed in black 96 well plates at 30°C with agitation at 1000rpm. Streptavidin Sensors (FortéBio) were hydrated for 20 minutes in kinetic buffer 0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20, pH 7.4 (GE healthcare), prior to loading of 3µg/ml of biotinylated ACE2 ligand for 180s. Following loading, the baseline signal was recorded for 120s in kinetic buffer. Sensors were then immersed into wells containing 2-fold serial dilutions of each recombinant SARS-CoV-2 RBD variant in kinetic buffer for 150 s (association phase) starting at 100nM, this was followed by immersion in kinetic buffer for 360s (dissociation phase). Curve fitting was performed using a global fit 1:1 binding model using Octet Data Analysis software v12.0.2.3 (FortéBio), and baseline drift was corrected by reference subtracting the shift of an ACE2 loaded sensor immersed in kinetic buffer only. Mean kinetic constant values from two independent experiments were determined, with all binding curves matching the theoretical fit with an r² value of > 0.99. The complex half-time (t½) in seconds was calculated using the formula: t½ = In2/k_dis=∼0.69/ k_dis.